Navigation Links
Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
Date:4/14/2008

NEW YORK, April 14 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation announced a $5.6-million award to drive a Phase 2 clinical trial to investigate the potential of inosine -- a naturally occurring chemical that gives rise to urate in the body -- to slow or stop the progression of Parkinson's disease.

The work is being funded under the Foundation's LEAPS (Linked Efforts to Accelerate Parkinson's Solutions) 2007 initiative. LEAPS 2007 was funded with a lead gift from the Edmond J. Safra Foundation, one of the most steadfast supporters of The Michael J. Fox Foundation since its inception.

Urate is a natural metabolite and major antioxidant in humans. Previous studies found that healthy people with higher urate levels in the blood had a reduced risk of developing PD. More recent work, including a study published today in the journal Archives of Neurology authored by two of the principal investigators on this LEAPS award, have linked higher urate levels to a possible slower progression of the disease.

The goals of this LEAPS award are to determine the safety of using inosine to raise urate levels, and to assess optimal dosage for therapeutic effect. Ninety people recently diagnosed with Parkinson's disease will be enrolled in a randomized, double-blind clinical trial to determine whether and at what dose inosine can safely elevate levels of urate in cerebrospinal fluid. Three months after enrollment, cerebrospinal fluid will be tested for urate levels. If a tolerable dose of inosine adequately increases urate in the cerebrospinal fluid, subjects will continue on treatment for up to two years to assess long-term safety.

"This project is precisely the sort of work that The Michael J. Fox Foundation exists to identify and drive forward for patients' benefit," said Katie Hood, the Foundation's CEO. "The study is based on interesting epidemiological observations, but because inosine is a publicly available compound, no corporate entity has the financial incentive to fund clinical research to definitively assess its potential. We believe it is our obligation to the PD community to step in where other funders may be unwilling to go, and ensure that innovative approaches like this one do not stall for lack of resources."

Inosine is widely available to consumers in dietary supplement form. The researchers emphasize that people with Parkinson's should not take inosine except in the context of a closely monitored clinical trial in which potential benefits and risks are carefully balanced. The evidence to date surrounding inosine and PD does not prove a cause-effect relationship. Additionally, elevated urate levels are known to carry certain health risks, only some of which have been definitively characterized to date. Kidney stones and gout are known risks; cardiovascular disease is a possible risk. (In the clinical trial, safety measures will be in place to help avoid these conditions, and to detect and treat them should they arise.)

LEAPS awards are multi-year, multi-million-dollar awards to teams of key experts who focus on answering major questions that can improve the diagnosis and treatment of Parkinson's disease. This third and final 2007 LEAPS award is the Foundation's single largest award to date. It brings the total funding under the 2007 LEAPS program to $13.8 million.

The principal investigators of this LEAPS award are:

-- Coordinating principal investigator Michael A. Schwarzschild, MD, PhD, of the MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, will oversee all elements of the trial.

-- Co-principal investigator Alberto Ascherio, MD, DrPH, of the Harvard School of Public Health, will assist in all aspects of trial design and data analysis and head the main biostatistician team.

-- Co-principal investigator Karl Kieburtz, MD, MPH, of the University of Rochester School of Medicine and Dentistry, heads the Clinical Trial Coordinating Center there and is chair of the Parkinson Study Group, a network of top researchers conducting clinical research in PD.

About The Michael J. Fox Foundation

Founded in 2000, The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease within the decade through an aggressively funded research agenda. The Foundation has funded over $120 million in research to date.


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
2. New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinsons Clinical Trials
3. Michael J. Fox Foundation Commits Up to $3 Million for Clinical Trials That Can Improve Treatment of Parkinsons Disease
4. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
5. Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings
6. Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
7. Gates Foundation Seeks Proposals for Innovative Global Health Research
8. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
9. Cystic Fibrosis Foundation Reports Upward Trend for Key Health Outcomes
10. Childrens Mental Focus Foundation Announces a Scientific Breakthrough for Children Who Have Been Diagnosed With Autism, ADD and ADHD
11. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... , May 22, 2017  As the ... a whole continue to make the revolutionary shift ... increasingly important for ensuring positive patient outcomes and ... stakeholders are shifting focus away from clinical trials ... effects of long-term specialty drug therapy utilization in ...
(Date:5/12/2017)... Canada joint tech company Laughing Face has developed ... and features a powerful disinfection process. The company has ... and sanitizes women,s panties or babies, cloth diapers in 25 minutes. ... Laughing ... external water inlet. ...
(Date:5/10/2017)... , May 10, 2017 Radiology has become ... its costs have also spiraled to the number one ... to radiology than ever before as the most complete ... a patient with lower back pain an MRI may ... reason for pain, resulting in entirely different treatment protocols.  ...
Breaking Medicine Technology:
(Date:5/22/2017)... Galena, Alaska (PRWEB) , ... May 22, 2017 , ... ... town near the Arctic Circle made big headlines when it was targeted to build ... Low-Cost Energy in Bush Alaska,” former city manager Marvin L. Yoder describes the journey ...
(Date:5/22/2017)... ... May 22, 2017 , ... WeightZone ... Wellocity to empower WeightZone Factor members to track their exercise patterns, monitor behavioral ... health education, all on their mobile phones. It also provides social networks for ...
(Date:5/21/2017)... ... ... Cornell, 52, was found dead on the night of Wednesday, May 17, 2017. It can ... the rock industry would take his own life, but the extremely talented and admired ... a role in the death of Chris Cornell . , Depression and Drug Use ...
(Date:5/21/2017)... ... May 20, 2017 , ... ... ABC Financial Services and financial systems. , Dozens of clubs using ABC ... are electronically processed through GetLinked into their club’s accounting system , The latest ...
(Date:5/21/2017)... WINTER PARK, FL (PRWEB) , ... May 20, 2017 , ... ... now sell it, find it, review it, and share its attributes like never before. ... online dispensary directory to connect cannabis enthusiasts to stores, strains, products – and for ...
Breaking Medicine News(10 mins):